Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Receivables - Net: 2014-2018

Historic Receivables - Net for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Dec 2018 value amounting to $24,000.

  • Viridian Therapeutics, Inc.\DE's Receivables - Net rose 1654.39% to $1.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.0 million, marking a year-over-year increase of 1654.39%. This contributed to the annual value of $24,000 for FY2018, which is 98.35% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Receivables - Net stood at $24,000 for FY2018, which was down 98.35% from $1.5 million recorded in FY2017.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Receivables - Net registered a high of $1.5 million during FY2017, and its lowest value of $20,000 during FY2016.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Receivables - Net value was $24,000 (recorded in 2018), while the average stood at $500,000.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Receivables - Net spiked by 7,180.00% in 2017 and then plummeted by 98.35% in 2018.
  • Viridian Therapeutics, Inc.\DE's Receivables - Net (Yearly) stood at $1.1 million in 2014, then plummeted by 63.79% to $394,000 in 2015, then crashed by 94.92% to $20,000 in 2016, then spiked by 7,180.00% to $1.5 million in 2017, then plummeted by 98.35% to $24,000 in 2018.